Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 7, 2012
- Accepted for publication June 27, 2012
- Published online September 28, 2012.
Article Versions
- Earlier version (August 2, 2012 - 06:25).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2012 by the American Society of Nephrology
Author Information
- Scott A. Reisman*,
- Glenn M. Chertow†,
- Sudarshan Hebbar*,
- Nosratola D. Vaziri‡,
- Keith W. Ward* and
- Colin J. Meyer*
- *Reata Pharmaceuticals, Inc., Irving, Texas;
- †Division of Nephrology, Stanford University School of Medicine, Palo Alto, California; and
- ‡Division of Nephrology and Hypertension, Schools of Medicine and Biological Science, University of California-Irvine, Orange, California
- Correspondence:
Dr. Scott A. Reisman, Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063. Email: scott.reisman{at}reatapharma.com
Statistics from Altmetric.com
Article usage
Cited By...
In this issue
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney
Jump to section
More in this TOC Section
Cited By...
- Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress
- Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3{beta} Reinforces the Nrf2 Antioxidant Defense against Podocytopathy
- Megalin-Mediated Tubuloglomerular Alterations in High-Fat Diet-Induced Kidney Disease
- Antioxidant resveratrol restores renal sodium transport regulation in SHR
- Is There a Sweet Spot for Nrf2 Activation in the Treatment of Diabetic Kidney Disease?
- The Proximal Tubule and Albuminuria: Really!
- New Treatments for CKD--New Insights into Pathogenesis